Revolution Medicines, Inc. Temporary Equity, Par Value
Revolution Medicines, Inc. (RVMD) had Temporary Equity, Par Value of $305.11 million as of 2019-12-31, per its 10-K filed 2021-03-02.
Discontinued › Balance Sheet › Temporary Equity › Temporary Equity, Other Disclosure
us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital · last filed 2021-03-02
- 2019-12-31: Temporary Equity, Par Value $305.11M.
| Period end | Temporary Equity, Par Value |
|---|---|
| 2019-12-31 | $305.11M 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |